Samsung Biologics unlocks additional capacity for production at its newest Plant 4


Samsung Biologics has commenced the Plant 4 GMP operations this month within just 23 months since groundbreaking, delivering on Samsung Biologics commitment made in 2020.

 Article Summary

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced today that its Plant 4 – the world’s largest single bio manufacturing plant – has commenced GMP operations this month.


A new production capacity of 60,000 liters has been added to Plant 4 in just 23 months since construction began in November 2020. As soon as it is completed in the first half of next year, Plant 4 will have a capacity of 240,000 liters. Plant 4 is expected to help Samsung Biologics maximize operational efficiency in addition to further enhancing its scale up development and manufacturing capability in response to growing biopharmaceutical demand.


“At the P4 groundbreaking ceremony in late 2020, we committed to have the plant up and running by October this year. I am very proud to have delivered on that promise, and confident that this will further solidify our position as a global leading CDMO,” said John Rim, CEO and President of Samsung Biologics. “As a trusted partner, we will continue investing domestically and globally to support our clients worldwide and provide expanded services.”


Samsung Biologics will boast a total capacity of 604,000 liters at Bio Campus I, the world’s largest bio manufacturing site, and account for nearly 30% of the global CDMO manufacturing capacity upon the full completion of Plant 4. Samsung Biologics has already sealed a number of large-scale manufacturing contracts with presales activities for Plant 4.


About Samsung Biologics Co., Ltd.

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

(Source: Samsung Biologics, October 11, 2022)


Leave A Comment

Leave a Reply

Your email address will not be published.